Valuation: Relay Therapeutics, Inc.

Market Cap 4.12B 3.6B 3.32B 3.08B 5.85B 391B 5.94B 39.83B 15.49B 193B 15.46B 15.13B 667B P/E 2026 *
-12.3x
P/E 2027 * -12x
Enterprise Value 3.83B 3.35B 3.09B 2.86B 5.43B 363B 5.52B 37.01B 14.39B 179B 14.37B 14.06B 620B EV / Sales 2026 *
305x
EV / Sales 2027 * 239x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day+6.46%
1 week+6.68%
Current month+6.68%
1 month+46.12%
3 months+48.07%
6 months+144.01%
Current year+135.93%
1 week 17.67
Extreme 17.67
20.15
1 month 13.19
Extreme 13.19
20.15
Current year 7.01
Extreme 7.01
20.15
1 year 3.02
Extreme 3.025
20.15
3 years 1.78
Extreme 1.775
20.15
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
06-29Sell

Executive/Senior Manager

-53,056 0.0277%
06-21Sell

Chief Financial Officer

-526,055 0.2746%
06-21Fiscal year

Chief Technology Officer

280,368 0.1463%
Change 5-day change 1-year change 3-year change Capi.($)
+6.43%+6.68%+462.25%+71.92% 4.12B
-1.03%+5.24%+2.94%+9.41% 50.25B
+1.01%+1.71%+419.44%+621.79% 40.39B
+1.07%+7.83%+28.25%-3.91% 34.38B
-0.73%+7.25%+26.82%+61.24% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.88%+2.15% - - 16.64B
-2.73%+3.54%+71.95%+132.81% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.80%+8.12%+105.19%+105.19% 13.75B
Average +1.20%+2.85%+126.26%+117.09% 25.01B
Weighted average by Cap. +0.54%+3.96%+102.06%+139.78%

Financials

2026 *2027 *
Net sales 12.55M 10.99M 10.13M 9.38M 17.82M 1.19B 18.1M 121M 47.21M 588M 47.13M 46.11M 2.03B 16.32M 14.28M 13.16M 12.2M 23.16M 1.55B 23.54M 158M 61.38M 765M 61.28M 59.95M 2.64B
Net income -288M -252M -232M -215M -409M -27.36B -416M -2.79B -1.08B -13.5B -1.08B -1.06B -46.67B -303M -266M -245M -227M -431M -28.8B -438M -2.93B -1.14B -14.21B -1.14B -1.11B -49.13B
Net Debt -292M -256M -236M -218M -414M -27.72B -421M -2.82B -1.1B -13.68B -1.1B -1.07B -47.28B -221M -193M -178M -165M -313M -20.96B -318M -2.14B -831M -10.35B -829M -811M -35.76B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-07-07 US$19.97 +5.66% 2,729,401
26-07-06 US$18.90 +1.34% 3,147,259
26-07-02 US$18.65 +5.01% 3,173,112
26-07-01 US$17.76 -5.08% 3,360,805
26-06-30 US$18.71 -5.22% 5,799,149
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.90USD
Average target price
24.82USD
Spread / Average Target
+31.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock